Abstract #0226

fMRI indicates central TRPV1 modulation on gouty pain

Chiao-Chi Chen¹, Yi-Hua Hsu¹, Yi-Jen Peng², Guo-Shu Huang³, and Chen Chang¹

¹Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, ²Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ³Department of Radiology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

Gout is one of the most painful forms of diseased conditions. Non-steroid anti-inflammatory drugs and colchicine are first-line agents for the acute attack, but these drugs are poorly tolerated or contraindicated in some patients. Elucidating the pain signaling pathway of gout may shed light on the key molecules that may be pursued as therapy targets in the future. Our neuroimaging, cellular, and molecular investigations regarding transient receptor potential vanilloid 1 (TRPV1) reveal a novel transduction pathway from the periphery to the brain during the attack of gout.

This abstract and the presentation materials are available to members only; a login is required.

Join Here